When used to treat most patients that had good visual potential, TCP was effective and safe; mTCP is even more so.
The MicroPulse P3 device has changed current thinking about cyclophotocoagulation in that it offers another option in the glaucoma treatment algorithm and allows for earlier laser intervention when medical treatment comes up short.
- Caprioli J, Strang SL, Spaeth GL. Cyclocryotherapy in the treatment of advanced glaucoma. Ophthalmology. 1985;92:947–954.
- Benson MT, Nelson ME. Cyclocryotherapy: a review of cases over a 10 year period. Br J Ophthalmol. 1990;74:103–105.
- Ansari E, Gandhewar J. Long-term efficacy and visual acuity following transscleral diode laser photocoagulation in cases of refractory and non-refractory glaucoma. Eye. 2007;21:936-940.
- Arjamaa O, Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res. 2006;83:473-483.
- Radcliffe N, Vold S, Kammer J, et al. MicroPulse trans-scleral cyclophotocoagulation (mTSCPC) for the treatment of glaucoma using the MicroPulse P3 device. Poster presented at the American Glaucoma Society annual Meeting. April 2015.